A study reported by Yasuhito Tanaka of the Nagoya City University Medical Department in Japan showed that the single nucleotide polymorphism (SNP) in the TLL1 gene is related to the occurrence and development of hepatocellular carcinoma after radical cure of hepatitis C virus infection. (Gastroenterology. 2017, 152: 1383-1394.) The researchers established different models by combining TLL1 gene mutation with other significant risk factors to predict the risk of liver cancer in patients with different degrees of liver fibrosis. TLL1 gene variants can be used to predict the risk of kansarka beerka in patients who have achieved a sustained virological response (SVR) in clinical practice. The study included Japanese patients who still suffered from liver cancer after interferon eradication of hepatitis C virus, and used genome-wide association analysis to identify which genes were mutated. The results showed that the TNP1 gene SNP rs17047200 on chromosome 4 is closely related to the occurrence of liver cancer after eradication of hepatitis C virus. There is no obvious linkage disequilibrium between other SNPs and rs17047200, and no more promising SNPs have been found in the exons and promoter regions of TLL1. Tanaka commented: “The mutant genes of liver cancer caused by hepatitis C virus include MICA and DEPDC5, which is very different from our test results.” In a multivariate analysis, the AT / TT base pairing of rs17047200 may lead to a 78% increased risk of liver cancer (P = 0.008). In the group of patients with mild fibrosis, older age is an independent risk factor for liver cancer; in the group of severe fibrosis, postoperative alpha-fetoprotein level and low albumin level are also risk factors. In two groups of liver fibrosis rat models, the mRNA level of TLL1 has increased, but only one group of models of TLL1 mRNA level is consistent with the progress of liver fibrosis. The level of TLL1 mRNA in patients with chronic hepatitis C also increases as liver fibrosis worsens.
Tananka ayaa tilmaamay: "Xogtani waxay markii hore muujineysaa xiriirka ka dhexeeya TLL1 / Tll1 iyo firfircoonida unugyada hepatic stellate ama horumarinta fibrosis cagaarshow ee xayawaanka ama in vitro iyo bini'aadamka (tusaale waa kansarka beerka ee steatohepatitis-ka aan khamriga ahayn). Waxa laga yaabaa inay awood u yeelato inay caddayso hab cusub oo ah beerka fibrosis ama kansar. Ka dib markii uu bukaanku helay daawaynta xagjirka ah ee fayraska cagaarshow C oo uu helo SVR, TLL1 SNP tijaaboyin la xidhiidha ayaa laga yaabaa in loo isticmaalo si loo ogaado dadka khatarta ugu jira kansarka beerka. Haddii TLL1 SNP la barbar dhigo Isku darka da'da, heerka fibrosis, heerka alfa-fetoprotein sare iyo arrimo kale oo khatar ah ayaa caawin kara kiliinikada saadaalinta khatarta kansarka beerka ka dib SVR. Ma jiro qorshe daawaynta afka interferon oo ay weheliso daawaynta daawada fayraska ka hortagga ee si toos ah u dhaqanta , Waxay noqonaysaa daawaynta caadiga ah ee ka hortagga fayraska cagaarshow C ee dalalka horumaray. Si kastaba ha ahaatee, cilmi-baaris dheeraad ah ayaa weli loo baahan yahay si loo qiimeeyo in isbeddellada TLL1 ay la xiriiraan dhacdada kansarka beerka ka dib daaweynta interferon-free SVR.
